Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for the treatment of ADHD
IRCT20090117001556N146Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sulforaphane in attention deficit hyperactivity disorder (ADHD), sponsored by Tehran University of Medical Sciences. Started Oct 2022; status: completed.
02
Drugs
sulforaphane
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20090117001556N146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N146.